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Abstract
The (pro)renin–renin receptor [(P)RR] was discovered as an important novel component of the renin–angiotensin system (RAS). The
functional significance of (P)RR is widely studied in renal and vascular pathologies and has sparked interest for a potential role in car-
diovascular disease. To investigate the role of (P)RR in cardiac pathophysiology, we aimed to assess (P)RR regulation in adverse car-
diac remodelling of the failing heart. In particular, we evaluated the expression of (P)RR in different models of heart failure and across
different species. Significantly increased levels of (P)RR mRNA were found in post-myocardial infarcted (MI) hearts of rats (1.6-fold, 
P  0.05) and mice (5-fold, P  0.01), as well as in transgenic rats with overexpression of the mouse renin gene (Ren2) (2.2-fold, P 
0.01). Moreover, we observed a strong increase of (P)RR expression in hearts of dilated cardiomyopathy (DCM) patients (5.3-fold, P 
0.001). Because none of the tested commercially available antibodies appeared to detect endogenous (P)RR, a (P)RR-specific polyclonal
antibody was generated to study (P)RR protein levels. (P)RR protein levels were significantly increased in the post-MI rat heart (1.4-
fold, P  0.05) as compared to controls. Most interestingly in DCM patients, a significant 8.7-fold (P  0.05) increase was observed.
Thus, protein expression paralleled gene expression. These results demonstrate that (P)RR expression is strongly up-regulated both in
rodent models of heart failure and in the failing human heart, hinting to a potential role for (P)RR in cardiac pathophysiology.
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Introduction
The renin angiotensin system (RAS) is a pivotal system in volume
and blood pressure regulation. For a long time, it was assumed
that its deleterious effects are exclusively mediated via its down-
stream effectors, angiotensin II and aldosterone [1, 2]. The
cloning of the (pro)renin–renin receptor [(P)RR] has, however,
challenged this paradigm [3]. Binding of both renin and its inac-
tive precursor, prorenin, to the (P)RR results in enhanced
(pro)renin activation in a non-proteolytic manner, and has an
approximately five-fold increase in renin catalytic activity as a
result. Thus, the netto tissue RAS activity by the classical sig-
nalling pathway involving angiotensin II formation and subsequent
activation of angiotensin II receptors may be augmented by
expression of (P)RR. Furthermore, evidence exists for angiotensin
II–independent effects of (P)RR as it is capable of intracellular
induction of the mitogen-activated protein kinase (MAPK) path-
ways, resulting in increased cell proliferation and up-regulation of
profibrotic genes [3].
Considerable interest therefore exists for the functional conse-
quences of (P)RR. (P)RR is expressed in kidney, specifically in renal
mesangial cells and in heart, brain, blood vessels, macrophages, 
T cells and granulocytes [3]. Although evidence exists that (P)RR
may be involved in renal pathophysiology [4–6], its potential role in
heart disease remains unclear. Ichihara et al. showed increased
mRNA expression of (P)RR in stroke-prone spontaneously hyper-
tensive rats (SHRsp) [7] and Hirose et al. showed increased mRNA
expression in rat hearts post-MI [8]. Whether other causes of car-
diac remodelling are associated with increased (P)RR expression,
whether (P)RR protein expression parallels mRNA expression 
and whether (P)RR is regulated in species other than rat, most
importantly human beings, is currently unknown.
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We herein present data on the transcript and protein expres-
sion of (P)RR in multiple models of murine and rat heart failure
and cardiac remodelling, as well as data from human heart failure.
Materials and methods
Cloning of mouse (P)RR
A full length mouse (P)RR cDNA (1060 base pairs encoding 350 amino
acids) was PCR amplified using a mouse kidney cDNA library (prepared
from pooled RNA of three C57Bl6/J males, 10 weeks old). For amplifica-
tion, the following primers were used: forward, CATGGCTGTGCTG-
GTCGTTCT and reverse, TCAATCTATTCGAATCTTCT. This PCR fragment
was cloned into the XhoI and HindIII sites of a pcDNA3.1 expression vec-
tor (Invitrogen, Darmstadt, Germany). For antibody generation, a Sau3A
DNA fragment (encoding amino acids 41–239) from the (P)RR binding
domain, denoted as (P)RR-BD, was cloned into the BamHI sites of the
Escherichia coli expression vector pQE31 (Qiagen, Venlo, Netherlands)
generating a 6xHis-tag fusion.
Protein expression and antibody generation
His6-(P)RR-BD expression in E. coli cells was induced by isopropyl--D-
thiogalactopyranoside (IPTG) for 4 hrs at 37C. His6-(P)RR-BD inclusion
bodies isolated in T10N50E1 buffer (10 mM Tris, pH 8.0; 50 mM NaCl; 1 mM
EDTA, 0.05% NP40) were dissolved in 6M Guanidine buffer (100 mM
NaH2PO4, 10 mM Tris-HCl and 6M Guanidine HCl, pH 8.0). His6-(P)RR-BD
was allowed to bind to Ni-NTA agarose beads (Qiagen) for 1 hr at room tem-
perature on a rotating shaker. Unbound protein was removed by washing the
beads with 8M urea buffer [100 mM NaH2PO4, 10 mM Tris-HCl and 8M urea,
pH 8.0). His6-(P)RR-BD was subsequently eluted with elution buffer (100 mM
NaH2PO4, 10 mM Tris-HCl and 8M urea, pH 4.5]. Finally, purified His6-
(P)RR-BD was separated on a SDS-PAGE gel, stained with 0.25M KCl and
isolated from the gel by electrophoresis in a dialysis bag for 3 hrs at 4C.
To generate a polyclonal antibody against (P)RR, purified recombinant
His6-(P)RR-BD was used for immunization of two rabbits. Immunization
was performed for every other week, and after the second, third and fourth
boosts blood samples were drawn to generate serum.
Titre test and purification of the antibody
(P)RR polyclonal antibody was purified using Schleicher and Schuell nitro-
cellulose membranes (0.45 m) containing immobilized purified recombi-
nant (P)RR. This membrane was blocked with [PBST (PBS0.5%
Tween)5% BSA] for 1 hr at room temperature and subsequently incu-
bated with serum for 2 hrs at 4C on a rotating wheel. Unbound antibody
was removed by washing with PBST six times. Finally, antibody was eluted
with 300 l glycine (100 mM, pH 2.8), and this was repeated five times.
Cell culture
HeLa S3 cells were cultured in DMEM with 4.5 g/l glucose supplemented
with 10% FCS, 100 U/ml penicillin and 100 g/ml streptomycin. Cells were
grown in a humidified incubator at 5% CO2 and 37C. For plasmid trans-
fection of HeLa S3 cells, lipofectamine LTX reagent (Invitrogen) was used.
Cells in a 12-wells plate with 60–80% confluency were transfected with 0.5
g DNA for 24 hrs.
mRNA expression and quantitative RT-PCR
Relative gene expression of (P)RR and atrial natriuretic peptide (ANP)
were determined by real-time polymerase chain reaction (RT-PCR). Gene
expression was normalized using reference genes 36B4 and GAPDH.
Values were expressed relative to appropriate control groups. The primers
used for the RT-PCR are summarized in Table S1.
Western blot
A total of 35 g of whole cell protein lysates were separated on a SDS-
PAGE gel and proteins were immunoblotted onto nitrocellulose mem-
branes. Membranes were incubated with rabbit polyclonal (P)RR primary
antibody (2 g/ml), goat polyclonal (P)RR primary antibody (Cat. no.
ab5959, 1 g/ml; Abcam, Cambridge, UK), goat polyclonal (P)RR primary
antibody (Cat. no. IMG-3561, 1 g/ml; Imgenex, San Diego, CA, USA),
mouse monoclonal p-ERK antibody (Cat. no. sc-7383, 0.2 g/ml; Santa
Cruz, CA, USA), mouse monoclonal ERK 1⁄2 antibody (Cat. no. sc-135900,
0.1 g/ml; Santa Cruz) or with rabbit monoclonal GAPDH primary antibody
(400 ng/ml; Fitzgerald Inc., North Acton, MA, USA). After incubation with
secondary polyclonal goat anti-rabbit (1:2000) or polyclonal rabbit anti-
goat (1:4000) or polyclonal rabbit antimouse (1:2000; Dako Inc. Glostrup,
Denmark) antibodies, proteins were detected using Super Signal West Pico
Chemiluminescent Substrate (Thermo Scientific Inc., Rockford, IL, USA).
The band densities were scanned and quantified using Syngene Bio
Imaging device and normalized to GAPDH.
Myocardial tissue specimen from patients with
heart failure
We have previously described the study population in detail [9]. Briefly, in
our diagnostic work-up, patients with DCM underwent cardiac catheteri-
zation and endomyocardial biopsies (EMB). EMB from the right ventricu-
lar septum were taken and snap-frozen. All patients had dilated, poorly
contractile left ventricles and were stable on medication. To study mRNA
levels, we tested EMB from 20 patients. For protein analysis, we used
heart tissue that was obtained during left ventriculectomy (n  3). Control
tissue was obtained from healthy human beings who donated their hearts
as organ donors, but whose hearts were refused because of surgical 
reasons (n  5).
Animal models and experimental protocols
We employed the established model of MI in both rats (n  5; Munich
Wistar Frömter, MWF) for 10 weeks and mice (n  6) for 4 weeks
(C57Bl6/J) by inducing coronary artery occlusion as previously described
[10]. Furthermore, we employed 6-week-old homozygous male TGR
(mREN2)27 rats (n  5), a model of fast-forward heart failure and
Sprague–Dawley (SD) control rats (n  5) as previously described [11].
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Rats were treated for six weeks with ACE inhibitor, lisinopril (10 g/ml), in
drinking water. Rats had ad libitum access to regular chow and drinking
water. At the end of six weeks, phenotyping was performed. Non-infarcted
part of hearts from post-MI animals and apex from the heart of Ren2 rats
were collected under anaesthesia and stored at 80C for further analysis.
All experiments were approved by the Animal Ethical Committee of the
University of Groningen, The Netherlands, and conducted in accordance
with existing guidelines for the care and use of laboratory animals.
Statistics
Data are expressed as mean 	 S.E.M. Differences were tested using
Student’s t-test or ANOVA, and results were considered statistically signifi-
cant when P-values were 0.05.
Results
Detection of (P)RR protein expression 
using various antibodies
Full length (P)RR consists of four domains, an N-terminal signal
peptide (a.a. 1–19), the extracellular ligand binding domain for
renin/(pro)renin binding (a.a. 20–303), (P)RR-BD, a single trans-
membrane domain (a.a. 304–326) and a short cytoplasmic
domain (a.a. 327–350; Fig. 1). For antibody generation, a frag-
ment of (P)RR-BD (a.a. 41–239) was expressed and purified and
used for generating a rabbit polyclonal antibody (Fig. 1). To test
this antibody, a Western blot with mouse heart tissue was probed
with the affinity purified antibody. As a positive control, a lysate
from transiently (P)RR expressing HeLa S3 cells was used and as
a control, non-overexpressing (P)RR HeLa S3 was used.
Expression of (P)RR in the transiently transfected HeLaS3 cells
was confirmed by RT-PCR (Fig. S1). As shown in Figure 2, this
(P)RR antibody recognized a band of 37 kD [the expected size of
(P)RR] in mouse heart lysates, which was also strongly present in
the positive control and barely present in the control HeLa S3
cells. This confirms the expression of (P)RR in the heart and the
specificity of our antibody. It is noteworthy that we also tested two
commercial available antibodies that have been used in some
other studies, but we could not detect a specific (P)RR signal with
these antibodies.
(P)RR expression in different organs
Having established (P)RR expression in the heart, we next inves-
tigated (P)RR expression in other organs. At the mRNA level, max-
imal (P)RR expression was observed in brain, followed by kidney,
intestine, liver and heart (Fig. 3A). In muscle and lung, expression
was nearly absent. At the protein level, maximal expression was
observed in kidney followed by liver, brain, heart and intestine
(Fig. 3B and C). Again, expression was low in muscle and lung.
Except for brain, mRNA and protein expression levels paralleled
each other.
Characteristics and expression of (P)RR in rats
and mice with post-MI heart failure
To investigate potential changes in (P)RR expression in post-MI
cardiac tissue, a coronary artery occlusion was performed in rats
and mice and cardiac remodelling ensued for 10 weeks in rats and
4 weeks in mice. Post-MI rats showed an infarct size of 
46.9 	 2.5%. Exact infarct sizes of the mouse hearts were not
assessed, but we scanned the mice with MRI and left ventricular
ejection fraction was 32% (normal mice: ~80%; Table S2). Heart
weights were significantly increased as compared to sham oper-
ated animals due to cardiac hypertrophy and remodelling. Ejection
fraction and fraction shortening were significantly reduced for both
rats and mice. In addition, in the non-infarcted parts of post-MI rat
hearts, ANP mRNA expression (14.7-fold, P  0.001) was strongly
increased and maximal contraction (P  0.05) and relaxation 
(P  0.05) of the left ventricular were all significantly decreased in
post-MI rats as compared to sham-operated animals (Table S2).
Post-MI rat hearts showed a significant increase in (P)RR
mRNA of about 1.6-fold (P  0.05) in the non-infarcted hypertro-
phied areas of the heart compared to sham-operated rats 
Fig. 1 Schematic depiction of (pro)renin–renin receptor. SP: signal peptide
(1–19 amino acids); (P)RR-BD: (P)RR binding domain (20–303 amino
acids); TM: transmembrane domain (304–326 amino acids); CD: cytoplas-
mic domain 327–350 amino acids). The domain for antibody generation is
indicated (41–239).
Fig. 2 Comparison of (P)RR expression using a newly generated (P)RR
polyclonal antibody and commercially available antibodies. Western blot
analysis for (P)RR expression in mouse heart tissue (marked as 1), control
HeLa S3 cells (marked as 2) and (P)RR-overexpressed HeLa S3 cells
(marked as 3). The newly developed antibody clearly detects a band at ~37
kD in 1 and 3 but not in the negative control lysate 2. The other two tested
antibodies (supplier 1 and supplier 2) detect a strong unspecific band at a
size of approximately 40 kD in 2 and 3 (marked with a *) and a faint band
at a size of about 37 kD in 1, 2 and 3. The 37 kD bands detected by the
commercial antibodies in lanes 2 and 3 were equally strong, suggesting
that this was not a (P)RR specific band.
J. Cell. Mol. Med. Vol 16, No 4, 2012
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(Fig. 4A). In mice, we demonstrate a more robust up-regulation of
approximately 5-fold (P  0.01; Fig. 4B) in the non-infarcted area.
Figure 4C displays (P)RR protein levels in non-infarcted area of
post-MI rat hearts, which were also significantly elevated by
approximately 1.4-fold (P  0.05; Fig. 4D).
ERK kinase activation during post-MI remodelling
Phosphorylated ERK kinase (expressed as p-ERK/ERK ratio) was
significantly increased by about 2.2-fold (P  0.05) in the rat
post-MI model. A significant positive correlation (r  0.730,
Pearson correlation coefficient; P  0.04) between (P)RR expres-
sion and ERK activation was observed, when compared to sham-
operated rats (Fig. S2).
Characteristics and (P)RR regulation in Ren2 rats
and effects of ACE inhibition
The Ren2 rat is a model that overexpresses mouse renin, result-
ing in hypertension and heart failure development. The HW/BW
ratio was significantly increased in Ren2 rats as compared to the
control SD group (P  0.01). ACE inhibition attenuated hyperten-
sion and prevented heart failure development in Ren2 rats. dp/dt
max (P  0.01) and dp/dt min (P  0.01) were significantly
decreased in Ren2 group when compared to control group. To
confirm the beneficial effects of ACEi treatment, we also measured
the expression of ANP mRNA levels which we report to be approx-
imately 12-fold (P  0.001) higher in untreated Ren2 rats,
whereas ACEi blunted the increase (2.7-fold, P  0.05) in expres-
sion (Table S2).
In the Ren2 rats, no significant differences in cardiac (P)RR
mRNA expression were detected compared to controls. However,
treatment with the ACEi, lisinopril, up-regulated (P)RR mRNA by
2.2-fold (P  0.01; Fig. 5A). To determine if the up-regulation of
(P)RR mRNA of lisinopril-treated Ren2 rats parallels (P)RR pro-
tein expression, we measured the expression in these groups and
found no significant difference (Fig. 5B). Thus, mRNA expression
does not always parallel protein expression.
Dilated cardiomyopathy up-regulates (P)RR
expression in human heart
To elucidate the regulation of (P)RR in human heart failure, we first
evaluated (P)RR expression of heart tissue from patients with DCM.
(P)RR mRNA levels were up-regulated significantly about 5.3-fold
(P  0.001) in the hearts of DCM patients compared to healthy con-
trols (Fig. 6A). In addition, protein levels of (P)RR showed a similar
up-regulation and was about 8.8-fold (P  0.05) higher in DCM
patients compared to healthy controls (Fig. 6B and C).
Discussion
The main findings of this study are that (P)RR mRNA and protein
expression are increased in cardiac remodelling and heart failure.
We tested heart tissue derived from a broad spectrum of experi-
mental models of cardiac remodelling and heart failure, from
 various aetiologies (pressure overload, ischaemia) and in different
species (mouse, rat). We corroborated our findings in human
 tissue specimens in which we also show an increased expression
of (P)RR. Finally, we report to have generated an anti-(P)RR anti-
body with higher specificity than currently available commercial
Fig. 3 Expression of (P)RR mRNA and protein in different organs of
C57Bl6/J mouse. (P)RR mRNA is highly expressed in brain, kidney, intestine
and liver and moderate in heart and undetectable in skeletal muscle and 
lung (n  4, A). (P)RR protein is highly expressed in kidney, brain, liver and
intestine, moderate in heart and undetectable in skeletal muscle and lung 
(n  4, B and C).
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antibodies, which we believe will be very helpful in future studies
into (P)RR.
The (P)RR was cloned in 2002 and has changed the paradigm
in thinking about the RAS considerably. Until then, it was believed
that circulating renin and (pro)renin themselves would be unharm-
ful, as their effects were thought to be conferred via downstream
elements of the RAS, specifically angiotensin II and aldosterone.
However, binding of renin/prorenin to the (P)RR has specific down-
stream effects in cell culture systems that mimic AngII [12, 13], for
example DNA synthesis, activation of stress-related kinases
(MAPK, ERK), activation of PAI-1 and phosphorylation of heat
shock proteins [3, 14, 15]. Furthermore, when (pro)renin or renin
binds the (P)RR, renin activity is higher so that ‘classical’ signalling
of the RAS is also increased. Thus, high levels of local (P)RR may
theoretically have profound impact on local RAS activity.
Despite this theorem, little knowledge exists on the role of (P)RR
in the heart, one of the main target organs of the RAS. Transcript
(mRNA) expression of (P)RR is up-regulated in the hearts of stroke-
prone spontaneous hypertensive rats (SHRsp) [7] and in the hearts
of rats with congestive heart failure [8]. So far, no data are available
on protein expression of (P)RR, especially in hearts of human
beings and rodents. We herein confirm previous reports on tran-
scriptional regulation of (P)RR in the rat heart with adverse cardiac
remodelling, and extend these findings to the protein level.
Moreover, we showed that this phenomenon is conserved in mice
and man. In fact, we observed that mRNA expression in post-MI
mice hearts and cardiomyopathic human hearts were even more
strongly up-regulated than in rat hearts. Again, using our new anti-
body, we could show for the first time that protein levels of (P)RR
are increased as well. Finally, we confirm the potential role of (P)RR
in adverse signalling pathways such as ERK kinase.
Although (P)RR was up-regulated in all models we tested, we
observed no increase in the TGR(mRen2) 27 rat (Ren-2 rat). To
assess further insight of (P)RR regulation in a high renin model,
we used this monogenic rat model with overexpression of the
murine renin-2 gene, resulting in hypertension and concomitant
Fig. 4 Elevation of (P)RR in post-MI heart. Both mRNA (in rat, n  5, A; and in mouse, n  6, B) and protein (in rat, n  4, C and D) expression of (P)RR
were significantly increased in non-infarcted areas of hearts of post-MI compared to sham-operated rats and mice. Data are expressed as mean 	 S.E.M.
*P  0.05, **P  0.01 versus control.
J. Cell. Mol. Med. Vol 16, No 4, 2012
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heart failure development. No significant up-regulation of (P)RR in
Ren2 compared to control rats was observed. It is possible that
the extreme high renin status does not represent a normal RAS
system, thereby not allowing typical RAS regulation, including
(P)RR. However, ACEi treatment of Ren2 rats increased (P)RR
mRNA expression significantly. This is in line with previous obser-
vations that blood pressure lowering drugs may increase (P)RR
expression in target organs [16, 17].
The study of the (P)RR has been hampered by the lack of a
specific antibody. We could not detect reliable results with cur-
rently commercial available antibodies. We therefore took the ini-
tiative to generate a specific antibody. Ongoing studies have
revealed that (P)RR is encoded by the ATP6AP2 gene and exists in
a truncated form that is 95% homologous to the ATP6AP2 gene
product, vacuolar-type H-ATPase (V-ATPase), the function of
which is to maintain acidic pH of intracellular vesicles [18]. This
function resides in C-terminal domain (amino acid 283–350). We
chose to raise an antibody with specific activity against the domain
of (P)RR (41–239 amino acids) that binds prorenin. We report
that the antibody detects a specific band at expected size (37 kD).
We compared our antibody with two other commercially available
antibodies and confirmed that only our self-generated antibody
detects (P)RR at the correct size. This new antibody may therefore
strengthen future studies into (P)RR.
A significant role for (P)RR in renal and vascular pathologies
has been proposed. (P)RR expression is increased in patients with
diabetic nephropathy and end-stage kidney disease [4], and animal
studies demonstrate up-regulation of renal (P)RR in rat models of
hypertension [6], diabetes [19] and renal injury [5]. Moreover,
transgenic rats overexpressing (P)RR in smooth muscle tissue
with strong transgene overexpression in the vasculature exhibit a
cardiovascular phenotype of elevated blood pressure and increased
heart rate [20]. However, definite proof of a role of (P)RR in cardiac
disease and heart failure is lacking. Mice in which the gene encod-
ing (P)RR is disrupted are not viable. The vacuolar-type H-ATPase
(V-ATPase) function of (P)RR seems an important conserved func-
tion that cannot be manipulated. Mice with cardiomyocyte-specific
disruption of (P)RR inevitably die of heart failure [21]. This study
Fig. 5 Regulation of (P)RR due to hypertensive therapy in rat heart
Comparison of the expression of (P)RR mRNA (A) and protein (B) in con-
trol (SD), Ren2, control (SD)ACEi, Ren2ACEi rats (n  5). Data are
expressed as mean 	 S.E.M. **P  0.01 versus Ren2.
Fig. 6 Up-regulation of (P)RR in the heart of human DCM. Heart tissues
were obtained from healthy control and dilated cardiomyopathy patients.
Both mRNA (n  20, A) and protein (n  3, B and C) expression were sig-
nificantly increased in DCM patients compared to healthy  controls. Data are
expressed as mean 	 S.E.M. *P  0.05, ***P  0.001 versus control.
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design does not allow for linking the measured (P)RR transcript
and protein levels to functional changes, which represents a limita-
tion. Future studies should unravel the role of the (up-regulated)
(P)RR in cardiac remodelling and heart failure.
In conclusion, we report both increased mRNA and protein
expression of (P)RR, in the failing hearts of various species and
with various aetiologies. We generated an antibody with specificity
against (P)RR that we believe will facilitate further elucidation of
(P)RR regulation. Our findings therefore implicate a role for (P)RR
in cardiac remodelling and heart failure.
Acknowledgements
This work was supported by the Netherlands Heart Foundation (grant
2007T046) and the Innovational Research Incentives Scheme program of
the Netherlands Organization for Scientific Research (NWO VENI, grant
916.10.117), both to Dr. de Boer.
Conflict of interest
The authors declare no conflict of interest.
Supporting information
Additional Supporting Information may be found in the online ver-
sion of this article:
Fig S1 RT-PCR analysis of (P)RR mRNA expression in control
HeLa S3 cells and (P)RR–overexpressed HeLa S3 cells.
Fig S2 (A) Representative Western blots showing activation of
ERK (phosphorylation and total ERK) in the non-infarcted
myocardium during post MI remodelling. (B) Changes in p-
ERK/ERK ratio of sham (gray fine bar) and MI (black bar) animals.
Data are expressed as means 	 SEM. N  4, *P  0.05 versus
sham. (C) Correlation analysis between (P)RR and ERK activation
during post MI.
Table S1 Primer sequences used in qRT-PCR.
Table S2 Animal Characteristics.
Please note: Wiley-Blackwell is not responsible for the content or
functionality of any supporting materials supplied by the authors.
Any queries (other than missing material) should be directed to
the corresponding author for the article.
References
1. Schroten NF, Gaillard CA, van Veldhuisen
DJ, et al. New roles for renin and prorenin
in heart failure and cardiorenal crosstalk.
Heart Fail Rev. 2011; doi: 10.1007/s10741-
011-9262–2.
2. Unger T, Li J. The role of the renin-
angiotensin-aldosterone system in heart
failure. J Renin Angiotensin Aldosterone
Syst. 2004; 5: S7–10.
3. Nguyen G, Delarue F, Burckle C, et al.
Pivotal role of the renin/prorenin receptor
in angiotensin II production and cellular
responses to renin. J Clin Invest. 2002;
109: 1417–27.
4. Takahashi K, Yamamoto H, Hirose T, 
et al. Expression of (pro)renin receptor in
human kidneys with end-stage kidney dis-
ease due to diabetic nephropathy.
Peptides. 2010; 31: 1405–8.
5. Hirose T,  Mori N,  Totsune K,  et al.
Increased expression of (pro)renin recep-
tor in the remnant kidneys of 5/6 nephrec-
tomized rats. Regul Pept. 2010; 159: 93–9.
6. Prieto MC, Williams DE, Liu L, et al.
Enhancement of renin and prorenin 
receptor in the collecting ducts of Cyp1a1-
Ren2 Rats contribute to development and
progression of malignant hypertension.
Am J Physiol Renal Physiol. 2010; 300:
581–8.
7. Ichihara A, Kaneshiro Y, Takemitsu T, 
et al. Nonproteolytic activation of prorenin
contributes to development of cardiac
fibrosis in genetic hypertension.
Hypertension. 2006; 47: 894–900.
8. Hirose T, Mori N, Totsune K, et al. Gene
expression of (pro)renin receptor is upreg-
ulated in hearts and kidneys of rats with
congestive heart failure. Peptides. 2009;
30: 2316–22.
9. de Boer RA, Henning RH, Suurmeijer AJ,
et al. Early expression of natriuretic pep-
tides and SERCA in mild heart failure:
association with severity of the disease. Int
J Cardiol. 2001; 78: 5–12.
10. de Boer RA, Pokharel S, Flesch M, et al.
Extracellular signal regulated kinase and
SMAD signaling both mediate the
angiotensin II driven progression towards
overt heart failure in homozygous
TGR(mRen2)27. J Mol Med. 2004; 82:
678–87.
11. de Boer RA, Pinto YM, Suurmeijer AJ,
et al. Increased expression of cardiac
angiotensin II type 1 (AT(1)) receptors
decreases myocardial microvessel density
after experimental myocardial infarction.
Cardiovasc Res. 2003; 57: 434–42.
12. Batenburg WW, Krop M, Garrelds IM,
et al. Prorenin is the endogenous agonist
of the (pro)renin receptor. Binding kinetics
of renin and prorenin in rat vascular
smooth muscle cells overexpressing the
human (pro)renin receptor. J Hypertens.
2007; 25: 2441–53.
13. Nabi AH, Kageshima A, Uddin MN, et al.
Binding properties of rat prorenin and
renin to the recombinant rat renin/prorenin
receptor prepared by a baculovirus expres-
sion system. Int J Mol Med. 2006; 18:
483–8.
14. Nguyen G, Delarue F, Berrou J, et al.
Specific receptor binding of renin on
human mesangial cells in culture increases
plasminogen activator inhibitor-1 antigen.
Kidney Int. 1996; 50: 1897–903.
15. Takahashi K,  Hirose T,  Mori N,  
et al. The renin-angiotensin system,
adrenomedullins and urotensin II in the
kidney: possible renoprotection via the kid-
ney peptide systems. Peptides. 2009; 30:
1575–85.
16. Feldt S,  Maschke U,  Dechend R,  
et al. The putative (pro)renin receptor
J. Cell. Mol. Med. Vol 16, No 4, 2012
729© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
blocker HRP fails to prevent (pro)renin
signaling. J Am Soc Nephrol. 2008; 19:
743–8.
17. Krebs C,  Hamming I,  Sadaghiani S,  
et al. Antihypertensive therapy upregu-
lates renin and (pro)renin receptor 
in the clipped kidney of Goldblatt 
hypertensive rats, Kidney Int. 2007; 292:
876–87.
18. Batenburg WW, Danser AH. The
(pro)renin receptor: a new addition to the
renin-angiotensin system? Eur J
Pharmacol. 2008; 585: 320–4.
19. Siragy HM, Huang J. Renal (pro)renin
receptor upregulation in diabetic rats
through enhanced angiotensin AT1 recep-
tor and NADPH oxidase activity. Exp
Physiol. 2008; 93: 709–14.
20. Burckle CA, Danser AH, Muller DN, et al.
Elevated blood pressure and heart rate in
human renin receptor transgenic rats.
Hypertension. 2006; 47: 552–6.
21. Kinouchi K, Ichihara A, Sano M, et al.
The (pro)renin receptor/ATP6AP2 is
essential for vacuolar H-ATPase assem-
bly in murine cardiomyocytes. Circ Res.
2010; 107: 30–4.
